Psilocybin Shows Promise During Active Cancer Treatment

Cancer treatment can ask patients to endure far more than the physical effects of disease. Depression, anxiety, fear, loss of identity, and questions about mortality can become just as difficult to navigate as the treatment itself. Yet many emerging therapies for psychological distress have been studied separately from the realities of active cancer care. However, that may be beginning to change.

Emerging research is examining whether psilocybin-assisted therapy could be used while patients are still receiving systemic anticancer treatment, a question that has largely remained unanswered because many psychedelic trials have excluded people undergoing active therapy. The findings do not necessarily establish psilocybin as a standard cancer treatment, but they may challenge an important assumption about who can safely participate in psychedelic research. And what researchers observed could help shape the next generation of supportive oncology studies. Let’s dive in.

Psilocybin Enters Supportive Oncology

Psilocybin is a naturally occurring psychedelic compound that can produce profound changes in perception, emotion, and cognition. In clinical research, however, psilocybin-assisted therapy is considerably different from simply taking a psychedelic substance.

The therapeutic model typically involves extensive preparation before dosing, a carefully supervised psychedelic session, and structured integration afterward. The goal is not simply to produce an altered state, but to use that experience within a controlled therapeutic framework.

In oncology, researchers have been particularly interested in whether this approach can help address depression and psychological or existential distress associated with cancer. That places psilocybin in a different category from medical cannabis. Cannabis has already become part of conversations surrounding symptom management, including pain, nausea and appetite concerns, often involving repeated or ongoing patient-directed use. Psilocybin-assisted therapy is being investigated as a much more structured, infrequent intervention focused primarily on psychological distress.

Why Active Cancer Treatment Matters

The research becomes especially important when systemic cancer treatment enters the picture. Chemotherapy, targeted therapies, immunotherapy, hormone therapy and other systemic treatments can affect the body in complex ways. Researchers therefore need to understand whether psychedelic therapy could interact with these treatments or create additional safety concerns.

Historically, many psilocybin studies involving cancer patients have excluded people receiving active systemic therapy. That has created a significant gap in knowledge. A therapy might appear promising among cancer survivors or patients who are not currently receiving systemic treatment, but that does not necessarily tell clinicians whether the same approach can be used while cancer treatment is ongoing. A 2026 secondary analysis of an earlier clinical trial began addressing that question.

What the Psilocybin Study Examined

Published online in August 2026, the research¹ was a secondary analysis of a phase II, open-label, single-arm clinical trial involving adults with cancer and major depressive disorder. The analysis included 30 participants. Seventeen were receiving systemic anticancer treatment around the time of psilocybin dosing, while 13 were not. Participants had a mean age of 56, and 70% were women.

Rather than treating psilocybin as a standalone drug intervention, participants underwent a structured course of therapy. The protocol included individual and group preparation, a single 25-milligram oral psilocybin dosing session conducted in a group setting, followed by individual and group integration therapy. Researchers then compared depression outcomes and adverse events between participants receiving active systemic cancer treatment and those who were not.

The question was relatively straightforward: Would psilocybin-assisted therapy appear substantially different in patients whose bodies were simultaneously dealing with systemic cancer treatment?

Depression Scores Fell in Both Groups

The results offered an intriguing answer. Depression symptoms declined substantially among participants receiving psilocybin-assisted therapy, and the improvement was comparable between those receiving systemic anticancer treatment and those who were not.

Researchers used the Montgomery–Åsberg Depression Rating Scale, or MADRS, to evaluate depression. Measurements were taken at one, three and eight weeks following treatment. Importantly, there were no statistically significant differences between the two groups at any of those time points. The between-group comparisons produced P values of .88 at week one, .93 at week three and .97 at week eight. In other words, the researchers did not find evidence that concurrent systemic cancer treatment diminished the antidepressant response observed following psilocybin-assisted therapy.

That does not necessarily prove that psilocybin will work equally well for every cancer patient. The study was small and lacked a randomized control group. However, it does provide an important signal for future research.

What Researchers Found About Safety

Safety was arguably the more important question. Adverse events were common in both groups, with an average of 9.0 events per participant among those receiving systemic treatment compared with 6.7 among those not receiving systemic therapy. That difference was not statistically significant. Additionally, four severe adverse events and one serious adverse event occurred among participants receiving systemic treatment. However, researchers determined that these events were not related to psilocybin. The analysis also found no significant laboratory or suicidality changes attributable to psilocybin.

These findings are encouraging, but they should not be interpreted as proof that psilocybin is universally safe for people undergoing cancer treatment. A sample of only 30 participants cannot identify uncommon complications or fully characterize potential interactions between psilocybin and the many medications used in modern oncology, and more research needs to be done to integrate psilocybin into cancer treatments. Instead, the results provide an argument for studying those questions more closely.

A Structured Model Makes a Difference

One notable aspect of the research is the treatment model itself. Psilocybin-assisted therapy is not equivalent to unsupervised psychedelic use. Participants in the study received preparation before the dosing session and integration afterward, with both individual and group components. That structure is particularly relevant in oncology, where psychological distress can be deeply connected to a person’s experience of diagnosis, treatment, uncertainty, and mortality.

The therapeutic process gives patients an opportunity to prepare for the psychedelic experience and later work through what emerged from it. That makes psilocybin-assisted therapy fundamentally different from the repeated, symptom-directed use often associated with medical cannabis.

The comparison is useful because cannabis has already forced oncology providers and regulators to confront questions about symptom relief, dosing, drug interactions and coordination with conventional treatment. Psilocybin may now be moving into a related conversation, but with a different therapeutic purpose and delivery model.

Why Psilocybin is Not Ready for Clinical Use

The study’s findings are promising, but they are not a green light for routine clinical use. The research was a small, nonrandomized secondary analysis. Without a larger randomized trial, researchers cannot determine how much of the observed improvement was specifically attributable to psilocybin, the therapeutic relationship, participant expectations, or other factors.

Drug interactions also remain an important unanswered question, as cancer patients may take multiple medications simultaneously, and different cancers require dramatically different treatment regimens. A finding that psilocybin-assisted therapy appeared comparable across a small group of patients cannot establish safety across every chemotherapy, immunotherapy, targeted therapy, or supportive medication. That is why larger safety and drug-interaction studies are needed before the approach could be considered broadly applicable.

A New Direction for Psychedelic Research

Perhaps the most significant implication is not that psilocybin has suddenly become a cancer treatment. It is that patients receiving active cancer treatment may deserve a place in the next generation of psychedelic research.

If future studies reproduce these results in larger and more diverse populations, psilocybin-assisted therapy could eventually become another tool within supportive oncology, not to treat tumors directly, but to help address the psychological and existential burden that can accompany cancer.

For now, the research offers something more measured but still meaningful: an early indication that receiving systemic cancer treatment does not necessarily prevent patients from benefiting from a carefully supervised psilocybin-assisted therapy model.

The next question is no longer simply whether psychedelics can help people with cancer. It may be whether they can be integrated safely and effectively into the realities of cancer treatment itself, and that is a question larger clinical trials are now positioned to answer.

References:

^{1. Daniel A. Schaefer, Manish Agrawal, Emanuele Mazzola, Michelle K. Leff, Celia Leeks, Benjamin S. Kematick, Yvan Beaussant, Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary Analysis, Journal of Pain and Symptom Management, 2026, ISSN 0885-3924, https://doi.org/10.1016/j.jpainsymman.2026.07.030}